Colossal Biosciences Stock

Colossal is a bioscience and genetic engineering company focused on de-extinction of past species.

Sign up today and learn more about Colossal Biosciences Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Colossal Biosciences Stock

Colossal creates disruptive technologies for extinct species restoration, critically endangered species protection, and the repopulation of critical ecosystems that support the continuation of life on Earth. The company is the first to apply CRISPR technology for the purposes of species de-extinction, beginning with the woolly mammoth. Colossal is accepting humanity’s duty to restore Earth to a healthier state, while also solving for the future economies and biological necessities of the human condition through cutting-edge science and technologies.

Funding History

May 2021$15.0M
March 2022$60.0M
January 2023$150M


Founder & CEO

Ben Lamm

Co-Founder & Chief Business Officer

Peter Phillips

Co-Founder + COO

Kent Wakeford

Chief of staff

Sarah Grant

VP of Strategy

Alexander Titus


Daniel Breyer

Executive Advisory Board

Adam Milne


Alexander Titus

Head of Software Marketing

Adam Weinroth

Head of Computational Sciences

Joe Nipko

Head of Biological Sciences

Eriona Hysolli


Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: